Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed "Stem Cell Treatments" for COVID-19.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32464095.
- Also identified by DOI 10.1016/j.stem.2020.05.003 and PMC identifier 7203029.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the midst of a global public health emergency, some businesses are taking advantage of widespread fears by marketing purported stem cell treatments for COVID-19. Such businesses target prospective clients with misleading claims, expose patients to potentially risky stem cell-based products, and undermine efforts to develop evidence-based treatments for COVID-19.
Medical subject headings
- Coronavirus Infections
- Marketing
- Pneumonia, Viral
- Stem Cell Transplantation